Does Foundayo help with perimenopause weight gain?

It can help eligible women lose weight, including those in perimenopause, based on Lilly's post-hoc trial data. It works on metabolism and appetite, not on menopause hormones.

How much weight did perimenopausal women lose on Foundayo?

In Lilly's ATTAIN-1 analysis, perimenopausal women without diabetes lost an average of 30.4 lbs (14.4%) over 72 weeks on the highest dose. In ATTAIN-2, perimenopausal women with type 2 diabetes lost 18.5 lbs (8.9%).

Yes. Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist — a small-molecule pill, not an injection.

Do you take Foundayo on an empty stomach?

No. Foundayo can be taken with or without food, at any time of day. This is one of its practical advantages over oral semaglutide (the Wegovy pill), which requires a strict empty-stomach morning routine.

Can Foundayo be used with HRT?

Foundayo slows gastric emptying, which can reduce absorption of oral medications including oral HRT and oral progesterone. Non-oral routes (patches, gels, IUDs) are less likely to be affected. Discuss your specific hormone regimen with your clinician before starting.

Does Foundayo affect birth control pills?

Yes. The label warns that oral contraceptives may be less effective on Foundayo due to its effect on gastric emptying. Lilly recommends switching to a non-oral method or using a barrier backup for 30 days after starting and after every dose increase.

Can I take Foundayo and HRT at the same time?

That's a clinician decision based on your specific hormone regimen. The concern is whether Foundayo's gut-slowing effect reduces absorption of your oral hormones. Non-oral hormone routes (patches, gels, IUDs) don't carry this risk. Bring your full medication list to your evaluation.

Can Foundayo be used while trying to get pregnant?

No. Foundayo's label says weight loss offers no benefit during pregnancy and may harm the baby. Use effective contraception while on it, stop it before attempting pregnancy, and discuss the washout period with your clinician. Breastfeeding is also not recommended while taking Foundayo.

Does Foundayo work better than HRT for perimenopause weight?

They treat different things. HRT addresses hormone deficiency and its symptoms (hot flashes, sleep, mood). Foundayo addresses weight through appetite and metabolism. For eligible women, both may be appropriate — but they aren't substitutes for each other.

How does Foundayo compare to Wegovy for perimenopause?

Foundayo (orforglipron pill) averages about 11–12% body-weight loss and can be taken any time with or without food. The Wegovy pill (oral semaglutide) requires a strict empty-stomach morning routine. The Wegovy injection averages higher loss but is a weekly shot. Those trial results come from separate studies, not a head-to-head comparison.

Is Foundayo covered by Medicare for perimenopause?

Starting July 1, 2026, eligible Medicare Part D members can access Foundayo for a $50 flat monthly copay through the Medicare GLP-1 Bridge — a temporary CMS program separate from normal Part D. It covers weight management, not perimenopause specifically. The $50 does not count toward your deductible or out-of-pocket total, and Extra Help (LIS) does not apply.

See if you qualify for Foundayo →Clinician evaluation · Insurance check · Ongoing support

Foundayo for Perimenopause: What the New Data Actually Shows

The honest 2026 answer — narrower and more useful than the headlines suggest.

By The RX Index Editorial Team · Last verified: June 11, 2026. The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We may earn a commission from some provider links — that never changes what we verify or whether we send you to a non-affiliate route when that's the better answer. This page is consumer information, not medical or legal advice.

The one-screen version

The bottom line	Best for	Not for	The numbers that matter
Foundayo may fit eligible perimenopausal women who want an FDA-approved oral weight-loss option — but it treats weight, not menopause.	Women with obesity (BMI 30+), or overweight (BMI 27+) plus a weight-related condition, who’d rather take a daily pill than a weekly shot.	Women whose main goal is hot-flash, sleep, or mood relief; anyone pregnant or trying to conceive; anyone with MTC or MEN 2 history.	30.4 lbs / 14.4% avg loss in the ATTAIN-1 perimenopause group (highest dose, 72 wks, no diabetes). ~4.9 in avg waist reduction.

See if you qualify.

A quick, no-pressure eligibility check with a licensed clinician will tell you whether Foundayo is appropriate for you — that’s the only opinion that counts.

Check Foundayo eligibility with Ro →Not sure? Take our free 60-sec quiz first

Ro’s membership fee is separate from medication. A clinician makes the prescribing decision.

We’re The RX Index — a pricing intelligence and comparison resource for GLP-1 telehealth providers. We don’t prescribe anything and we don’t sell medication. What we do is verify the facts — pricing, FDA status, safety, and access — so you can have a faster, smarter conversation with a real clinician.

What we actually verified for this page

We split every claim into three buckets — regulatory, clinical, and commercial — and checked each against the most direct source we could find. Here’s the receipt.

What we checked	What we found	Source
FDA status	Foundayo (orforglipron) is FDA-approved for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition. It is not approved for perimenopause or menopause.	FDA prescribing info; Lilly approval (Apr 1, 2026)
Perimenopause data	Lilly reported post-hoc subgroup results by menopause stage from ATTAIN-1 and ATTAIN-2, presented at the 2026 ADA Scientific Sessions (June 7, 2026).	Lilly / PR Newswire [3]
The birth-control interaction	The label says oral birth control "may not work as well" on Foundayo, and advises a non-oral method or backup for 30 days after starting and after each dose increase.	FDA prescribing info / Lilly safety summary [1][3]
Cost	LillyDirect self-pay starts at $149/mo (lowest dose) and rises by dose to $349; eligible commercially insured patients may pay as little as $25/mo.	foundayo.lilly.com coverage page [4]
Medicare	Eligible Part D members can access Foundayo for a $50 flat copay through the Medicare GLP-1 Bridge starting July 1, 2026 — outside normal Part D.	CMS [6]

Everything below is built on those facts.

Is Foundayo good for perimenopause weight gain?

Answer capsule

For the right woman, yes — but read the word “right” carefully. Foundayo can produce real, meaningful weight loss in perimenopausal women who meet the FDA-approved criteria (obesity, or overweight with a weight-related condition). It is not a treatment for perimenopause itself.

The uncomfortable thing first — because it’s the thing that protects you:

Foundayo does not fix perimenopause. If your main struggle is hot flashes, night sweats, broken sleep, mood changes, brain fog, or vaginal symptoms, Foundayo is the wrong tool — that’s a conversation about menopause care and possibly hormone therapy, and you should start there. But if you’re nodding along to a different story — the one where you eat the way you always have, move the way you always have, and the scale climbs anyway, with the weight settling around your middle for the first time in your life — then you’re looking at the question this page exists to answer.

Foundayo may fit you if you:

✓Have obesity (BMI 30+), or overweight (BMI 27+) with a weight-related condition like high blood pressure, high cholesterol, or obstructive sleep apnea
✓Want an FDA-approved GLP-1 you take as a daily pill, not a weekly injection
✓Are frustrated by midlife weight gain and want clinician-guided treatment
✓Don't want the strict empty-stomach morning routine oral semaglutide requires

Look elsewhere first if you:

✗Mainly want symptom relief — hot flashes, sleep, mood, vaginal dryness (start with menopause care)
✗Are pregnant, trying to conceive, or planning a pregnancy
✗Already have a GLP-1 that's working for you
✗Want the single largest average weight loss and are open to a weekly shot

One honest tradeoff to know up front:

Foundayo averaged about 11–12% body-weight loss in its own trials — less than the strongest injectable, tirzepatide (Zepbound), which averaged roughly 20% in its trials. (Those are separate studies, not a head-to-head, so treat it as a ballpark, not a scoreboard.) If the single largest possible loss is your goal and needles don’t bother you, an injectable may take you further — and we’ll say so plainly rather than paper over it.

Not sure if you qualify? Our free 60-second quiz walks you through the criteria and the options.

Start the free quiz →See the broader GLP-1 for perimenopause guide →

What did the Foundayo perimenopause study actually show?

Answer capsule

The strongest perimenopause-specific data comes from Lilly’s 2026 post-hoc analysis of its ATTAIN-1 and ATTAIN-2 trials, covering more than 1,500 women. On the highest dose at 72 weeks, perimenopausal women without diabetes lost an average of 30.4 lbs (14.4%); with type 2 diabetes, 18.5 lbs (8.9%). These are subgroup results, not a separate FDA approval.

What “post-hoc analysis” means — and why it matters

Researchers went back after the trial finished and sorted the women by menopause stage to see how each group did. It’s a legitimate, useful way to look at the data — but it’s not the same as a trial designed from the start to prove Foundayo treats perimenopause. Keep that distinction in your pocket; it’s the thing most pages blur.

All figures below are for the highest dose (17.2 mg) at 72 weeks, from Lilly’s June 7, 2026 data release.

ATTAIN-1: women without type 2 diabetes

Group	Women	Starting weight	Avg. weight change	Lost ≥15%	Waist change
Pre-menopause	171	219.1 lbs	−12.8% (−28.0 lbs)	40.9%	−4.5 in
★ Perimenopause	142	217.6 lbs	−14.4% (−30.4 lbs)	51.5%	−4.9 in
Post-menopause	152	208.6 lbs	−14.1% (−28.2 lbs)	45.4%	−4.8 in

ATTAIN-2: women with type 2 diabetes

Group	Women	Starting weight	Avg. weight change	Lost ≥15%	Waist change
Pre-menopause	10	237.9 lbs	−11.3% (−23.4 lbs)	36.4%	−4.3 in
Perimenopause	33	209.7 lbs	−8.9% (−18.5 lbs)	20.4%	−3.3 in
Post-menopause	109	202.2 lbs	−13.6% (−27.8 lbs)	44.2%	−4.3 in

Source: Eli Lilly, post-hoc analyses of ATTAIN-1 and ATTAIN-2, presented at the 2026 American Diabetes Association Scientific Sessions (June 7, 2026). Trials used an investigational formulation of orforglipron. These are subgroup results, not a separate FDA approval.

What this table actually tells you — and what it doesn’t

The headline is real.

In the perimenopause group without diabetes, more than half the women (51.5%) lost at least 15% of their body weight, and the average loss beat both the pre- and post-menopause groups. That's a strong signal for women in exactly your stage.

"Up to" is doing real work.

That 30.4 lbs is the average for women on the highest dose who stayed on treatment. Your result depends on your dose, how well you tolerate it, your diet and activity, and whether you stick with it. It's a realistic ceiling, not a promise.

Diabetes changes the math.

The perimenopause-with-diabetes group lost less (8.9%) and was small (33 women). If you have type 2 diabetes, set your expectations against the ATTAIN-2 row, not the headline.

The waistline matters as much as the scale.

Midlife weight tends to land around the abdomen, and that deep belly fat is the metabolically risky kind. The roughly 4.9-inch average waist reduction in the perimenopause group is arguably the more important number for long-term health.

One more piece of honesty: endocrinologists at NewYork-Presbyterian / Weill Cornell found that tirzepatide (Zepbound) produced roughly 20% weight loss across pre-, peri-, and post-menopausal women too. The takeaway researchers keep landing on: these are metabolic medications, not menopause medications — and the data suggests eligible women can still lose meaningful weight at every menopause stage.

Is Foundayo FDA-approved for perimenopause or menopause?

No — and this matters more than it sounds.

Foundayo is FDA-approved for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition — used together with a reduced-calorie diet and more physical activity. Perimenopause might be why you’re researching weight gain, but perimenopause by itself is not the approved reason to prescribe it.

You don’t qualify for Foundayo because you’re in perimenopause. You qualify because of your BMI, your health history, and your weight-related conditions. A clinician makes that call.

The right questions to bring to your appointment

→Based on my BMI and health, do I meet the criteria for Foundayo?
→Is an oral GLP-1 a reasonable fit for me specifically?

To be completely clear: Foundayo is not approved to treat — and should never be described as treating — hot flashes, night sweats, mood changes, vaginal symptoms, or hormone imbalance. It is a weight-management medicine for eligible adults. If anyone implies otherwise, close the tab.

How much does Foundayo cost in 2026?

Answer capsule

Foundayo self-pay pricing through LillyDirect starts at $149/month for the lowest dose and rises by dose up to $349/month. Eligible commercially insured patients may pay as little as $25/month, and eligible Medicare Part D members may access it for a $50 copay through the Medicare GLP-1 Bridge beginning July 1, 2026. If you use a telehealth provider for the visit and ongoing care, that membership fee is separate from the medication.

Foundayo cost by dose — LillyDirect self-pay, 30-day supply

Dose	Self-pay price	The catch worth knowing
0.8 mg (starter)	$149/mo	Everyone begins here. Lowest cost.
2.5 mg	$199/mo	First step up.
5.5 mg	$299/mo	Common maintenance range.
9 mg	$299/mo	Same price as 5.5 mg.
14.5 mg	$299/mo (or $349)	$299 only if you refill within 45 days; otherwise $349.
17.2 mg (highest)	$299/mo (or $349)	Same 45-day refill rule applies.

Source: foundayo.lilly.com coverage & savings page. Verify current pricing before relying on it — Lilly can change these terms.

The number most pages quietly skip:

That $149 is the starter dose, not your long-term cost. Most people titrate up over a few months, so budget closer to the $299 maintenance range — and know that the two highest doses only stay at $299 if you keep your refills inside that 45-day window. Miss it, and you’re at $349.

Will insurance, Medicare, or HSA/FSA cover Foundayo?

Path	What you might pay	The fine print that matters
Commercial insurance + Foundayo Savings Card	As low as $25/mo	Only if you have commercial drug insurance that covers Foundayo and meet Lilly's eligibility rules. Government beneficiaries excluded; savings have monthly and annual limits; current card terms expire 12/31/2026 unless changed.
LillyDirect self-pay	$149–$349/mo by dose	The most transparent, predictable route if you're uninsured, not covered, or waiting on prior authorization.
Medicare GLP-1 Bridge (from July 1, 2026)	$50/mo flat copay	For eligible Part D members meeting CMS criteria. Runs outside normal Part D — the $50 does not count toward your deductible or out-of-pocket (TrOOP) total, Extra Help (LIS) does not apply, and extra coupons can't lower it further. Temporary program transitioning to BALANCE Model in 2027.
HSA/FSA	Plan-dependent — don't assume	Lilly's self-pay card terms say you agree not to seek reimbursement from an HSA, FSA, or other third-party account for costs bought with the card. Some telehealth or prescription expenses may be HSA/FSA-eligible — confirm with your plan administrator.

Quick gut-check before you pick a route:

Already have a prescriber and just want predictable pricing → compare LillyDirect self-pay pricing.

Need an evaluation, side-effect support, and help checking insurance → a full-service telehealth provider handles all three.

Check eligibility with Ro — and see if your insurance covers it →

Ro’s free coverage checker contacts your insurer and sends you a personalized report.

What’s the best way to get Foundayo if you’re in perimenopause?

Answer capsule

The best route depends on what you already have. Foundayo is prescription-only no matter which door you pick — someone licensed has to say yes. If you need an evaluation, insurance help, and ongoing care, a full-service telehealth provider is the cleanest path. If your own doctor already agrees, LillyDirect is the most direct option.

Foundayo access routes compared

Your situation	Best route	Why	What to know
"I need an online evaluation and help checking insurance."	Ro	FDA-approved Foundayo access, a clinician who monitors side effects and dose changes, plus an insurance concierge that handles prior-authorization paperwork.	Membership is separate from medication. Ro Body is $39 the first month, then $149/mo (or as low as $74/mo with annual prepay). Medication is billed separately; Ro prices Foundayo in line with LillyDirect's self-pay rates ($149–$349 by dose). Free GLP-1 insurance checker available.
"My doctor already agrees Foundayo is right for me."	LillyDirect	The official, direct-from-manufacturer route once you have a prescription.	Transparent self-pay pricing ($149–$349 by dose). No membership.
"I want a clinician who really knows menopause."	Menopause-focused telehealth	Foundayo discussed alongside HRT and the rest of your midlife care, not in isolation.	Program fees vary — verify before you commit. Menopause specialty means better hormonal context, not necessarily better weight-loss results.
"I want a familiar women's telehealth brand."	Hers	A consumer brand many women already use, now offering FDA-approved GLP-1 options.	Membership about $39 the first month, then $149/mo; medication not included. A fine fit if you already use it — not automatically the best value.

Our take, plainly:

For a perimenopausal woman who wants Foundayo and wants a professional to evaluate her, watch for side effects, manage the dose climb, and check coverage, Ro is the route we’d point to first. Not because it’s the only option — LillyDirect is right there for people who already have a prescription — but because most people researching this don’t yet have a clinician on board, and a guided start gives you more clinical support than a discount card and a “good luck.”

Start your evaluation with Ro →Compare LillyDirect pricing instead →

What providers claim vs. what we verified

Route	Public claim	What we verified	Still verify yourself
LillyDirect	Self-pay from $149/mo; $25/mo with commercial insurance	Confirmed on Lilly's own coverage page, including the 45-day refill rule and savings-card limits	Current pricing (can change)
Ro	FDA-approved Foundayo access; ~11% average loss in 1 year; insurance concierge	Foundayo is live on Ro; membership structure and insurance checker confirmed; 11% matches the trial average	Ro's exact current Foundayo per-dose price
Hers	Oral GLP-1 program; $39 first month then $149/mo	Membership pricing and 'medication not included' confirmed on the Hers Foundayo page	Current Foundayo availability and any waitlist
Sesame	FDA-approved Foundayo, once-daily pill, provider choice	Foundayo listing and self-pay framing confirmed	Exact visit/program fees (not publicly fixed)

Can you take Foundayo with HRT, progesterone, or birth control?

This is the single most important perimenopause-specific question on this page — don’t skip it.

Foundayo slows how fast your stomach empties, which can affect how your body absorbs oral medications. Its label specifically warns that birth control pills may not work as well — and advises switching to a non-oral method, or adding a backup, for 30 days after you start and for 30 days after each dose increase.

Oral birth control

Many women in perimenopause still use the pill — for cycle control, symptoms, or contraception. The label’s plain-terms guidance: your pill may be less reliable on Foundayo. Lilly recommends either switching to a non-oral method (like an IUD, patch, ring, or implant) or using a barrier method for 30 days after starting Foundayo, and for 30 days after every dose increase. Since you’ll likely raise your dose several times during titration, that’s several windows to plan around. This isn’t a do-it-yourself change — it’s a conversation to have before your first dose.

Oral HRT and oral progesterone

Foundayo’s label doesn’t lay out a specific menopause-hormone protocol. But the same gut-slowing effect that makes the pill less reliable raises a fair question about oral hormone therapy and oral progesterone — both of which depend on stomach absorption. Menopause specialists have flagged this exact concern with incretin-based medications. The British Menopause Society’s guidance notes that delayed gastric emptying may reduce absorption of oral HRT components, and that non-oral routes may be preferable for some women. If you rely on oral progesterone for endometrial protection, that’s not a detail to wing. Bring it up directly.

The good news: non-oral routes sidestep most of this

Transdermal estrogen (patches, gels) doesn’t rely on stomach absorption at all, and an IUD doesn’t either — so these routes are far less likely to be affected by Foundayo’s gut-slowing. For a lot of women, the clean answer is simply moving hormones off the oral route. But that’s your clinician’s call, not ours.

Bring these exact questions to your appointment — save or screenshot this:

☐Will Foundayo make my oral birth control less effective?
☐Should I use backup contraception during each dose increase, and for how long?
☐I take oral progesterone — does it still protect my uterine lining on Foundayo, or should I switch routes?
☐Would transdermal estrogen or an IUD be a smarter fit while I'm on this?
☐Do any of my other daily pills need their timing adjusted?

This isn’t a sales moment — it’s a safety one. Getting this right is the difference between a smooth start and an avoidable problem.

Who should not take Foundayo — or should ask a clinician first?

Foundayo is prescription-only and isn’t safe for everyone.

Run through this honestly before you get attached to the idea.

⚠

Do not take Foundayo if you or a family member has had medullary thyroid carcinoma (MTC), or if you have MEN 2. The label warns it may cause thyroid tumors, including cancer. Watch for a neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath.

⚠

Do not take Foundayo if you've ever had a serious allergic reaction to orforglipron or any ingredient in it.

⚠

Do not combine Foundayo with another GLP-1. If you're already on one, tell the clinician before switching or adding anything.

⚠

Pancreatitis, gallbladder, or severe stomach problems: tell your clinician about any history. Severe, lasting abdominal pain means stop and call right away.

⚠

Diabetes medication: if you use insulin or a sulfonylurea, your risk of low blood sugar goes up. This needs a plan.

⚠

Diabetic retinopathy: if you have it, mention it — rapid blood-sugar improvement has been linked to temporary worsening in some cases.

⚠

Dehydration and kidneys: the GI side effects can dehydrate you, which can strain your kidneys. Push fluids; call if vomiting or diarrhea won't quit.

⚠

Pregnancy and breastfeeding: Foundayo is not a weight tool for pregnancy. The label says weight loss offers no benefit during pregnancy and may harm the baby; stop it if you become pregnant, and breastfeeding is not recommended while taking Foundayo.

⚠

Surgery or anesthesia: because it slows stomach emptying, tell your surgical and anesthesia team you're taking it.

If any of these apply to you, start with our matching quiz instead — so you get routed to an option that actually fits your health.

Take the 60-second matching quiz →

What side effects matter most for women in midlife?

Answer capsule

Most of Foundayo’s common side effects are gastrointestinal — nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, swollen belly, belching, heartburn, and gas — plus headache, fatigue, and hair loss. For most women, the real question isn’t whether the drug works; it’s whether they can tolerate it long enough to benefit.

Foundayo side effects that hit different in perimenopause

Label-listed effect	Why it matters more in midlife	What to ask your clinician
Nausea, vomiting, diarrhea (GI)	Worst early and after each dose bump; the top reason people quit before they benefit	"Can we titrate slowly, and what helps me push through the first few weeks?"
Hair loss	Many women already notice hormonal hair thinning in perimenopause, so this can feel alarming	"How do I protect my hair — protein, labs, pace of weight loss?"
Appetite drop → low protein	Menopause already speeds muscle and bone loss; eating too little protein on top of that risks losing lean muscle, not just fat	"What's my protein target, and should we track muscle or do labs?"
Dehydration → kidney strain	GI side effects plus the lower fluid intake common in busy midlife days	"What are my dehydration warning signs, and when do I call you?"

The midlife issue most pages ignore: muscle.

GLP-1 medications cut appetite — sometimes so much that women under-eat protein, right when menopause is already chipping away at muscle and bone. Lose lean muscle along with fat and you undercut your strength, your metabolism, and your bones. So if you use Foundayo in perimenopause, pair it with adequate protein and resistance (strength) training — treat those as part of the prescription, not optional extras. This is the single most important thing we can tell a midlife woman about doing this well.

Call a clinician promptly if you have: severe or lasting stomach pain, repeated vomiting, signs of dehydration, an allergic reaction (swelling, trouble breathing), vision changes (if you have diabetes), or gallbladder-type pain in your upper right belly.

Does Foundayo fix “meno belly,” cravings, or menopause symptoms?

Foundayo can reduce body weight and waist size in eligible women, including those in perimenopause — but it is not a fix for menopause symptoms. It does nothing for hot flashes, night sweats, mood, sleep, or hormone balance. Here’s a clean truth table to keep the marketing honest.

The claim	True?	What’s accurate
"Foundayo treats perimenopause."	❌ No	It treats chronic weight management in eligible adults — not perimenopause.
"Perimenopausal women lost weight on Foundayo in a Lilly analysis."	✅ Yes, with caveats	~30.4 lbs / 14.4% average in the ATTAIN-1 perimenopause group on the highest dose — a post-hoc subgroup result.
"Foundayo fixes hot flashes."	❌ No	No evidence. Don't expect it.
"Foundayo reduces waist size."	✅ Supported	~4.9 inches average in the perimenopause group.
"Foundayo replaces HRT."	❌ No	It is not hormone therapy and is not a substitute for menopause care.

So which problem are you actually solving? Not sure which bucket you’re in?

Our quiz sorts it out in 60 seconds →

Foundayo vs. the Wegovy pill vs. Zepbound: which fits perimenopause?

Answer capsule

Foundayo’s edge is convenience — it’s an FDA-approved oral GLP-1 you can take any time, with or without food. The Wegovy pill (oral semaglutide) also requires a strict empty-stomach morning routine. Zepbound is a weekly injection that tends to produce the largest average weight loss. The “best” one depends on your priorities, not a leaderboard.

Option	Form	Biggest advantage	Biggest drawback	Best fit
Foundayo	Once-daily pill	No needles; no food/water timing	Newer; ~11–12% average loss, lower than the top injectable	Wants oral convenience and will actually stick with it
Wegovy pill	Daily oral semaglutide	Familiar Wegovy/semaglutide name	Must take on an empty stomach, in the morning, with strict timing rules	Can follow a strict daily routine
Zepbound	Weekly injection	Largest average weight loss in this group (~20% in its trials)	It's an injection	Wants maximum results and is fine with a weekly shot

Why Foundayo often wins for a perimenopause reader:

It removes friction. Between work, family, shifting sleep, and a hormone routine, the medication that requires the least daily choreography is the one you’ll keep taking — and consistency beats a marginally better trial number you abandon in month three.

Why it might not win for you:

If your single priority is the largest possible weight loss and needles don’t faze you, an injectable like Zepbound may take you further. Don’t force the pill.

See our full Foundayo vs. Zepbound comparison →Foundayo vs. the Wegovy pill →

What should you ask before starting Foundayo during perimenopause?

Copy this and bring it to your appointment. Walking in with a short list makes it faster, safer, and far more useful than “what do you think, doc?”

1Based on my BMI and health history, do I actually meet the FDA-approved criteria for Foundayo?
2Does an oral GLP-1 make sense for me, or would an injectable fit better?
3How should I handle my oral birth control during each dose increase?
4Does Foundayo affect my oral HRT or progesterone? Should I switch to a patch or IUD?
5What side effects should make me call you — or stop?
6What will I likely pay at the maintenance dose you expect me to reach?
7How will we protect my muscle and bone — protein targets, strength training, labs?
8What happens if I can't tolerate moving up to the next dose?

Want this turned into a personalized starting plan?

The right route, an honest cost estimate, and the safety flags for your situation — in 60 seconds.

Take the free 60-second matching quiz →

How The RX Index verified this page

We’re The RX Index — a pricing intelligence and comparison resource for GLP-1 telehealth providers. For this page, we separated regulatory facts, clinical-trial facts, and commercial facts, and verified each against the most authoritative source available before offering any editorial opinion.

Our source order:

1. FDA prescribing information for the approved use, dosing, contraindications, warnings, and drug-interaction language.
2. Lilly’s clinical-data release (ATTAIN-1 and ATTAIN-2 post-hoc analyses, ADA 2026) for the menopause-stage results.
3. Lilly / LillyDirect and CMS for pricing and coverage.
4. Menopause clinical guidance for the oral-hormone absorption considerations.

Our rule on money: affiliate relationships do not decide FDA status, safety language, or whether a provider fits you. When a non-affiliate route (like LillyDirect) is the better answer for your situation, we say so on the page. We didn’t personally complete a Foundayo prescription visit with each provider, and we didn’t verify every state’s availability or every provider’s full program fees — those carry a “verify before relying on it” flag. We didn’t use any social-media post, or any paid provider testimonial, as medical evidence.

Foundayo for perimenopause — FAQs

The questions women search right after learning Foundayo has perimenopause data but isn’t a menopause drug. Each answer is meant to stand on its own.

Is Foundayo approved for perimenopause?: No. Foundayo is FDA-approved for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition — not for perimenopause or menopause symptoms.
Does Foundayo help with perimenopause weight gain?: It can help eligible women lose weight, including those in perimenopause, based on Lilly's post-hoc trial data. It works on metabolism and appetite, not on menopause hormones.
How much weight did perimenopausal women lose on Foundayo?: In Lilly's ATTAIN-1 analysis, perimenopausal women without diabetes lost an average of 30.4 lbs (14.4%) over 72 weeks on the highest dose. In ATTAIN-2, perimenopausal women with type 2 diabetes lost 18.5 lbs (8.9%).
Is Foundayo a GLP-1?: Yes. Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist — a small-molecule pill, not an injection.
Do you take Foundayo on an empty stomach?: No. Foundayo can be taken with or without food, at any time of day. This is one of its practical advantages over oral semaglutide (the Wegovy pill), which requires a strict empty-stomach morning routine.
Can Foundayo be used with HRT?: Foundayo slows gastric emptying, which can reduce absorption of oral medications including oral HRT and oral progesterone. Non-oral routes (patches, gels, IUDs) are less likely to be affected. Discuss your specific hormone regimen with your clinician before starting.
Does Foundayo affect birth control pills?: Yes. The label warns that oral contraceptives may be less effective on Foundayo due to its effect on gastric emptying. Lilly recommends switching to a non-oral method or using a barrier backup for 30 days after starting and after every dose increase.
Can I take Foundayo and HRT at the same time?: That's a clinician decision based on your specific hormone regimen. The concern is whether Foundayo's gut-slowing effect reduces absorption of your oral hormones. Non-oral hormone routes (patches, gels, IUDs) don't carry this risk. Bring your full medication list to your evaluation.
Can Foundayo be used while trying to get pregnant?: No. Foundayo's label says weight loss offers no benefit during pregnancy and may harm the baby. Use effective contraception while on it, stop it before attempting pregnancy, and discuss the washout period with your clinician. Breastfeeding is also not recommended while taking Foundayo.
Does Foundayo work better than HRT for perimenopause weight?: They treat different things. HRT addresses hormone deficiency and its symptoms (hot flashes, sleep, mood). Foundayo addresses weight through appetite and metabolism. For eligible women, both may be appropriate — but they aren't substitutes for each other.
How does Foundayo compare to Wegovy for perimenopause?: Foundayo (orforglipron pill) averages about 11–12% body-weight loss and can be taken any time with or without food. The Wegovy pill (oral semaglutide) requires a strict empty-stomach morning routine. The Wegovy injection averages higher loss but is a weekly shot. Those trial results come from separate studies, not a head-to-head comparison.
Is Foundayo covered by Medicare for perimenopause?: Starting July 1, 2026, eligible Medicare Part D members can access Foundayo for a $50 flat monthly copay through the Medicare GLP-1 Bridge — a temporary CMS program separate from normal Part D. It covers weight management, not perimenopause specifically. The $50 does not count toward your deductible or out-of-pocket total, and Extra Help (LIS) does not apply.

Related guides

Sources

1.[1] FDA — Foundayo (orforglipron) Prescribing Information (approved use, contraindications, warnings, drug interactions, pregnancy): https://pi.lilly.com/us/foundayo-uspi.pdf
2.[2] FDA — Foundayo Approval (April 1, 2026): https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-foundayo
3.[3] Eli Lilly / PR Newswire — ATTAIN-1 and ATTAIN-2 post-hoc menopause-stage analyses, presented at the 2026 ADA Scientific Sessions (June 7, 2026). Includes perimenopause group weight-loss data, waist reductions, birth-control label language, and boxed warning: https://investor.lilly.com/news-releases/news-release-details/lilly-presents-new-foundayo-orforglipron-data-showing-weight-loss
4.[4] Lilly / LillyDirect — Foundayo cost and savings page (self-pay pricing by dose, savings card terms, HSA/FSA restriction, 12/31/2026 card expiry): https://foundayo.lilly.com/savings-support/foundayo-cost-and-coverage
5.[5] Lilly / LillyDirect — Direct pharmacy access to Foundayo: https://www.lilly.com/lillydirect/medicines/foundayo
6.[6] CMS — Medicare GLP-1 Bridge demonstration program ($50 copay, July 1, 2026 – Dec 31, 2027, three eligibility tiers, TrOOP non-applicability, Extra Help non-applicability): https://www.cms.gov/newsroom/fact-sheets/medicare-glp-1-bridge-demonstration
7.[7] NewYork-Presbyterian / Weill Cornell — Tirzepatide weight loss across menopause stages (~20% across pre/peri/post-menopausal women): https://weillcornell.org/news/study-finds-tirzepatide-works-equally-well-regardless-of-menopause-status
8.[8] Ro — Foundayo access, membership pricing, insurance concierge, and free GLP-1 insurance checker: https://ro.co/weight-loss/foundayo/
9.[9] British Menopause Society — Guidance on GLP-1 medications and oral hormone absorption (delayed gastric emptying; non-oral HRT routes for women on incretins): https://thebms.org.uk/publications/tools-for-clinicians/gnrh-analogues-and-hrt-management-of-the-menopause-in-women-using-glp-1-receptor-agonists/
10.[10] Hers — Foundayo program page (membership $39 first month, then $149/mo; medication separate): https://www.forhers.com/weight-loss/foundayo
11.[11] Sesame — Foundayo listing (FDA-approved, once-daily pill, provider choice, self-pay framing): https://sesamecare.com/service/online-weight-loss-program

Foundayo and orforglipron are trademarks of Eli Lilly and Company. This page is independent and not affiliated with Eli Lilly, Ro, Sesame Care, or Hers.

Update log. Last verified June 11, 2026. Next review: July 11, 2026. Immediate update triggers: a Lilly pricing change, an FDA label update for orforglipron, a CMS Bridge rule change, or a British Menopause Society guidance update.

Related guides